The genetic aetiology of a large proportion of intellectual disability (ID) cases still remains undiagnosed as de novo mutations (DNMs) in protein coding regions of the genome explain only 35-40% of the cases 1,2 . We sequenced whole genomes of 70 individuals, including 24 ID probands, to identify potentially pathogenic DNMs at distal cis-regulatory elements, as they may explain some of these genetically undiagnosed ID cases. In our cohort, DNMs were significantly enriched in fetal brain specific enhancers that were intolerant to mutations within the human population.
Introduction
Intellectual disability (ID) is a neurodevelopmental disorder that is characterized by limitations in both intellectual functioning and adaptive behavior 1 . The worldwide prevalence of ID is thought to be 1% 3 , which provides a significant medical and social challenge to our society. The clinical presentation of ID tends to be highly heterogeneous and often occurs along with congenital malformations or other neurodevelopmental disorders such as epilepsy and autism 1 . The methods to establish aetiological diagnosis in patients with ID have been significantly improved in recent years 4 . The genetics is known to play a significant role in the aetiology of ID 1 . With the introduction of next generation sequencing (NGS) technologies, over the past decade, great progress has been made in identifying genetic causes of ID. It has been shown that de novo protein truncating mutations and de novo copy number variations play a crucial role in the aetiology of ID 2, 5 . Large numbers of genes have been implicated in ID and related neurodevelopmental disorders 1 , however, mutations in coding regions of the genome only explain up to 35-40% of ID cases 2 .
The genetic aetiology of a large proportion of ID cases still remains unidentified. De novo mutations (DNM) in non-coding regions of the genome, specifically distal cis regulatory elements (CRE), could explain some of the cases in which no causal pathogenic coding mutation has been identified. However, to date, limited efforts have been made to understand contribution of enhancer mutations in ID.
Previous studies have implicated CRE mutations in monogenic developmental disorders including preaxial polydactyly (SHH) 6, 7 , Pierre Robin syndrome (SOX9) 8 , congenital heart disease (TBX5) 9 and pancreatic agenesis (PTF1A) 10 . In addition, sequencing of evolutionarily ultra-conserved regions in developmental disorder probands found enrichment of DNMs only in fetal brain enhancers 11 . On the contrary, large-scale whole genome sequencing of autism spectrum disorder (ASD) patients along with unaffected parents and unaffected siblings (quad) has found no significant association between any non-coding classes other than promoter regions with ASD 12 . In the case of coding mutations, only protein truncating mutations, which make up a relatively small fraction of all coding mutations, show significant enrichment in neurodevelopmental disorders 12, 13 . Unlike protein coding regions, it is challenging to distinguish between potentially pathogenic mutations and benign mutations in distal CREs due to the absence of codon structure. The brain is the most complex organ in the body. During brain development, various lineage specific genes need to be expressed in the right amount, at the right time, and at the right location. The spatio-temporal expression of genes is regulated by distal CREs. It has been shown that the disease-associated variants are enriched in diseases relevant tissues 14 . Thus, DNMs in fetal brain specific (FBS) enhancers that regulate expression of essential brain developmental genes could affect brain morphogenesis with severe functional consequences. Furthermore, advanced human cognition has been attributed to human brain enhancers that are gained during evolutionary expansion and elaboration of the human cerebral cortex 15 . It is therefore possible that DNMs in human gained (HG) enhancers could have a significant impact on human cognition.
In the present study, we performed whole genome sequencing of 70 individuals, including 24 ID probands and their unaffected parents. To understand the role of distal cis-regulatory mutations, we specifically focused on FBS and HG enhancers.
We performed an extensive experimental validation and showed that the majority of enhancer DNMs tested in this study lead to significant loss or gain of enhancer activity. Perturbation studies of putative CSMD1 enhancer lead to a striking transcriptional phenotype suggesting a contribution of CSMD1 enhancer DNMs in neurodevelopmental disorders.
Results

Whole genome sequencing and identification of de novo mutations
We performed whole genome sequencing (WGS) of 70 individuals including 24 probands with severe intellectual disability (ID) and their unaffected parents at an average genome wide depth of 37X (supplementary table 1). Our cohort includes 22 trios and one quad family with two affected probands. We identified on average 4.08 million genomic variants per individual that include 3.36 million single nucleotide variants (SNVs) and 0.72 million short indels (supplementary table 1). We focused our analysis mainly on de novo mutations (DNMs), as it has been shown that DNMs contribute significantly to neurodevelopmental disorders 5, 16 . We identified a total of 
Protein coding de novo mutations and copy number variants
The role of protein truncating mutations in ID is well established; hence we first looked at DNMs located in protein coding regions of the genome. A total of 23 DNMs were located in the protein coding regions of the genome (average 1.1 DNMs per proband). Of the 23 coding mutations, 15 were non-synonymous coding mutations or protein truncating mutations. In six ID probands, we identified various types of pathogenic mutations in the genes KAT6A, TUBA1A, KIF1A, NRXN1 and PNKP all of them previously implicated in ID 2, 18 . The mutation in KAT6A gene resulted in a premature stop codon while genes TUBA1A and KIF1A showed non-synonymous coding mutations that were reported to be pathogenic in ClinVar 19 (supplementary   table 4 ). One de novo CNV resulted in partial deletion of known ID gene NRXN1. A family with two affected siblings was analyzed for the presence of recessive variants.
We identified a homozygous 17bp insertion in the gene PNKP (supplementary table 4) in both siblings. This insertion has been reported as pathogenic in ClinVar 19 .
De novo mutations in cis-regulatory elements (CRE)
In our severe ID cohort, we did not identify pathogenic coding DNMs in 17 ID cases (~70%); hence we decided to investigate potentially pathogenic mutations in distal cis-regulatory regions (CRE) of the genome. To increase the statistical power, we included 30 previously published severe ID samples in which no pathogenic protein coding DNMs have been found using WGS 2 . We hypothesized that the DNMs in fetal brain specific distal CRE could perturb expression levels of genes that are essential for brain development, leading to ID. We identified 27,420 fetal brain specific enhancers using epigenomic roadmap data 14 (see Methods). In addition, we included 8,996 human gained enhancers that have been shown to be active during cerebral corticogenesis 15 .
A total of 83 DNMs (an average of 1.77 DNMs per proband) were located within fetal brain specific or human gained enhancers. To test the enrichment of observed number of DNMs in fetal brain specific enhancers and human gained enhancers we used previously defined framework for interpreting DNMs 20 . In short, the model determines mutability of a given base by taking into consideration one nucleotide on each side (trinucleotide context). We used DNMs identified in healthy individuals in genome of the Netherlands (GoNL) 21 to test the suitability of the mutational model for estimating expected number of DNMs in enhancer regions. In healthy individuals the observed number of DNMs (n=252) was almost equal to expected number of DNMs (n=250) in fetal brain specific enhancers (P=0.53; Figure1), suggesting that the mutational model fits well to determine expected number of DNMs within tissue specific enhancers. Next, we investigated the enrichment of observed number of DNMs over expected in fetal brain specific enhancers and human gain enhancers within the ID cohort. As a control we used multiple fetal and adult tissue specific enhancers as well as a set of randomly selected, sequence composition matched quiescent regions. The fetal brain specific enhancers and human gained enhancers showed enrichment for DNMs in our ID cohort as compared to the expected number of mutations, however enrichment was statistically not significant (P = 0.10; Figure1).
However, fetal brain specific enhancers showed significant enrichment when compared to fetal lung specific enhancers as a control (P = 0.038). Almost all the non-brain tissue specific enhancers and control quiescent regions showed depletion of DNMs in ID patients. Our results demonstrate that the enhancers from disease relevant tissues are specifically enriched for DNMs in this disease cohort.
Recurrent DNMs in fetal brain specific or human gained enhancers
Due to the smaller sample size, we were not able to identify individual enhancers with recurrent DNMs hence we investigated whether clusters of enhancers that regulate the same gene show recurrent DNMs. To identify clusters of enhancers that target the same gene, we used the following approaches: neuronal progenitor cells (NPC) promoter capture Hi-C (PCHi-C) data 22 ; correlation of H3K27ac signal at promoters and enhancers across multiple tissues; and promoter-enhancer correlation using chromHMM segmentation data. If any enhancer remained unassigned after application of these approaches, we assigned the closest fetal brain expressed gene as a target gene of the enhancer. For all approaches, we restricted our search space to brain topologically associated domains (TADs) 23 as the majority of enhancerpromoter interactions happen within TADs 24 . The enhancer clusters associated with three genes, CSMD1, OLFM1 and POU3F3 showed recurrent mutations within our cohort (supplementary figure 1) . The presence of three enhancer clusters with recurrent DNMs was significantly higher than expected (P = 0.016).
Biological properties of genes associated with DNM-containing enhancers
To investigate whether enhancer associated genes have previously been implicated in ID or related neurodevelopmental disorders, we used three gene sets; known ID genes 2, 18 , genes implicated in neurodevelopmental disorders in DDD project 16 and autism risk genes (SFARI genes) 25 . This provided us with a unique set of 1,868 genes previously implicated in neurodevelopmental disorders. The genes associated with DNM-containing enhancers were enriched for known neurodevelopmental disorder genes (25 genes, P = 0.025, supplementary table 5). Furthermore, the putative target genes of DNM-containing enhancers were involved in nervous system development (P = 7.4x10 -4 , supplementary table 6) and were predominantly expressed in the prefrontal cortex (P =6.5 x10 -3 supplementary table 7), the region of the brain that has been implicated in social and cognitive behavior, personality expression, and decision-making.
The potential functional effect of enhancer mutations may be through altered expression target genes. Recently, it has been shown that the majority of known severe haploinsufficient human disease genes are intolerant to loss of function (LoF) mutations 26 . We compared the putative target genes of DNM-containing enhancers with the recently compiled list of genes that are intolerant to LoF mutations (pLI >=0.9) 26 . We found that a significantly higher proportion of enhancer DNM target genes were intolerant to LoF mutations than expected (P = 4.2x10 -5 , supplementary table 8). Taken together, this analysis suggests that haploinsufficiency of fetal brain specific genes involved in nervous system development due to CRE mutations could lead to severe ID.
Population constraints in fetal brain specific enhancers and human gain enhancers
It has been shown that single nucleotide changes in enhancer regions can lead to severe developmental defects 10 . On the contrary, recent studies suggest that functional redundancy of enhancers of developmental genes reduce the likelihood of severe functional consequences of enhancer mutations 27 . We reasoned that enhancers that are essential for human cognitive development must be intolerant to mutations within the human population. Hence we investigated whether fetal brain specific enhancers themselves are intolerant to mutations. The recently developed context dependent tolerance score (CDTS) provides sequence constrains across human population in non-coding regions of the genome at 10bp resolution 28 . The human gain enhancers as well as fetal brain specific enhancers showed significant enrichment (P < 2.2x10 -16 and P < 2.2x10 -16 respectively) for constrained genomic regions (CDTS <=30, figure 2A ) when compared to sequence composition matched control regions. This finding suggests that enhancers that regulate spatio-temporal expression of genes during brain development tend to be intolerant to mutations. In our ID cohort, 25 enhancer DNMs were located within constrained regions (CDTS score <= 30) of the genome and the majority (13 out of 25) of them were associated with at least one loss of function intolerant (pLI >= 0.9) gene (figure 2C). We found marginal enrichment of DNMs in constrained enhancers (CDTS<=30) as compared to control quiescent regions (P=0.072; Figure 2B ). However, when we restricted the analysis to highly constrained regions (CDTS<=20), we found significant excess of DNMs (P=0.027; Figure 2B ) in fetal brain specific enhancers as compared to control regions. An increased burden of DNMs in ID patients in enhancers that are intolerant to mutations within the human population suggests that DNMs in populationconstrained regions are more likely to be functional, specifically if they are associated with loss of function mutation intolerant genes.
Effect of DNMs on transcription factor binding sites
Enhancers regulate gene expression through the binding of sequence-specific transcription factors (TFs) at TF binding sites (TFBS) within the enhancer 29 . DNMs that alter the sequence of putative TFBS or create putative TFBS within the enhancer region could have a significant impact on target gene expression. Of the 82 de novo SNVs, 32 were predicted to alter putative TFBS affinity strongly, either by destroying or creating TFBS (supplementary table 9 ).
Functional validation of DNMs using luciferase reporter assays
DNMs in enhancers could have severe functional consequences, specifically if they regulate intolerant genes. To test the functional impact of regulatory mutations on enhancer activity, we investigated 11 enhancer DNMs (supplementary table 10) using luciferase reporter assays in a neuroblastoma cell line SH-SY5Y. Of the 11 DNM containing enhancers, 10 showed at least one allele (wild type or mutant) with significantly higher activity than the negative control, suggesting that these putative enhancers are indeed active enhancers in this neuronal cell line. Of 10 active enhancers, nine showed allele specific activity with five showing loss of activity and four showing gain of activity due to DNMs (Figure 3 ). The majority of the DNMs that showed allele-specific enhancer activity altered the core base of the TF motif with position specific weight >= 0.95 (supplementary table 9 ). Both the DNMs in the putative CSMD1 enhancer cluster showed gain of activity compared to the wild type allele, while both OLFM1 enhancer DNMs showed loss of activity due to DNMs.
These results demonstrate that the DNMs in fetal brain specific enhancers or human gain enhancers that significantly alter TF binding affinity are more likely to be functional.
Functional validation of CSMD1 enhancer DNM using CRISPR interference
We identified recurrent DNMs in the CSMD1 enhancer cluster with two DNMs (chr8:
2177122C>T and chr8: 2411360T>C) from two unrelated ID probands (fam6 and fam3 respectively). Both the probands showed developmental delay and both were overgrown with high birth weights (above the 91st centile) and remain large. Both CSDM1 enhancer DNMs resulted in gain of enhancer activity (Figure 3 ). The CSMD1 gene is involved in neurogenesis 30 and has been shown to be associated with schizophrenia 31 . Motif analysis predicted that the DNM chr8:2411360T>C from fam3 disrupts the binding site for the transcriptional repressor TCF7L1 32,33 ( Figure   4A ). TCF7L1 is known to inhibit premature neurogenesis 34 Figure 4D ), probably due to repression by TCF7L1, we differentiated these cells into neurons. Differentiated neurons with CRISPRi of CSMD1 enhancer showed significantly higher expression of CSMD1 than control cells (P=0.004; Figure 4B ). The KRAB domain is known to repress transcription through heterochromatin spreading 35, 36 or simply by steric interference of endogenous regulatory components 37 . In this case it is possible that the transcriptional repressor TCF7L1 may not be able to bind at the TFBS due to heterochromatinisation or obstruction of the CSMD1 enhancer leading to overexpression of CSMD1.
To investigate the detailed molecular phenotype of CRISPRi at CSMD1, we performed RNAseq upon differentiation of neuronal precursors to neurons. RNAseq data shows significant up-regulation of CSMD1 in CRISPRi inactivated neurons as compared to controls. In addition, the genes MYH3 (myosin heavy chain 3), expressed exclusively during embryonic development, and PCDHGA11 (Protocadherin Gamma-A11), which plays a significant role in establishment of cellcell connections in the brain, showed a significantly strong down-regulation ( Figure   4C ). Up-regulation of CSMD1 and down-regulation of MYH3 and PCDHGA11 suggest that CSMD1 regulatory DNM chr8:2411360T>C may affect the formation of axons and the establishment of neuronal connections, which might be a potential cause of ID in the fam3 proband.
We observed that CSMD1 was not expressed in LUHMES cells while TCF7L1 was highly expressed ( Figure 4D ). Inversely, in differentiated neurons, CSMD1 showed a high expression while a striking down-regulation was observed for TCF7L1 compared to the undifferentiated state ( Figure 4D ). Analyzing gene expression of CSMD1 and TCF7L1 across multiple tissues using GTEx data 38 , we found that the expression pattern of both of these genes were almost mutually exclusive. In tissues where TCF7L1 was expressed at high levels, CSMD1 did not show any expression.
On the contrary, CSMD1 showed expression only in the tissues where TCF7L1
showed relatively lower levels of expression ( Figure 4E ), strengthening our assumption that TCF7L1 represses CSMD1 in LUHMES cells. Taken together, our analysis shows that the DNM in the putative CSMD1 enhancer might affect the binding of the transcriptional repressor TCF7L1, leading to premature expression of CSMD1. This could be the potential mechanism by which enhancer DNM leads to ID in this patient.
Next, we explored occurrence of DNMs in the CSMD1 enhancer cluster in largescale WGS studies on autism spectrum disorders (ASD). The Simons Simplex Collection (SSC) has sequenced WGS of 1,902 ASD families (quad) 12 , while the MSSNG database has compiled WGS of 2,281 ASD trios 17 . Within the SSC cohort, four DNMs from unrelated ASD cases were located in the CSMD1 enhancer cluster, while unaffected siblings did not contain any DNM in CSMD1 enhancer cluster.
Additionally, we found four ASD patients from the MSSNG database harboring DNMs in the CSMD1 enhancer cluster. Presence of a total of eight DNMs in ASD cohort suggests that DNMs in CSMD1 enhancer cluster tend to be highly penetrant in neurodevelopmental disorders.
Discussion
This study provides strong clues about the role of disease relevant tissue specific enhancers in severe ID as we see a marginal enrichment of DNMs in fetal brain specific enhancers. However, an absence of ways to distinguish potentially pathogenic mutations from benign regulatory mutations makes it challenging to determine the true burden of pathogenic mutations in CREs. Aggregation of a minority of the pathogenic mutations with the majority of benign regulatory mutations nullifies any signal from pathogenic mutations in the disease cohort 12, 13 .
The large majority of the DNMs tested in this study showed allele-specific activity.
The majority of validated DNMs alter core bases of the motif with position weight >=0.95 in the position specific weight matrix. This reiterates the fact that DNMs that alter core bases of the TF binding motif strongly alter TF binding affinity, thus are more likely to be functional 39 . Furthermore, enrichment of DNMs in the enhancers that are intolerant to mutations within human populations suggests that the DNMs in essential enhancers are more likely to be functional. This study shows that the tissue specificity of enhancers, population constraint and changes in TF binding affinity are some of the key factors that could determine the pathogenicity of the enhancer DNMs. To confirm these findings and to identify additional properties of potentially pathogenic regulatory DNMs, functional validation of a large number of enhancer DNMs from large-scale WGS studies 13, 17 , using high throughput assays such as massively parallel reporter assays 40 or BiT-STARR-seq 41 , is required. Furthermore, to understand the role of regulatory mutations in ID and other neurodevelopmental disorders it is important to understand the functional genomic architecture of brain tissue at various developmental stages 42 . Improved annotation of functional enhancers using epigenomic profiling methods, together with genome-wide reporter assays and accuracy in identifying enhancer-promoter interactions using promoter capture Hi-C 43 and Hi-ChIP 44 , would significantly improve identification of potentially pathogenic of regulatory mutations.
We showed that a DNM in a transcriptional repressor binding site leads to overexpression of CSMD1, a gene involved in neurogenesis. The majority of previously reported pathogenic regulatory mutations in monogenic disorders have been shown to abolish enhancer activity [6] [7] [8] [9] [10] . At least to our knowledge, mutations in a repressor-binding site that lead to a monogenic disorder have not yet been documented. However, such reports can be found in common diseases and cancer 45, 46 . The obesity risk allele associated with FTO was shown to disturb a conserved motif for the ARID5B repressor, leading to IRX3 and IRX5 overexpression during early adipocyte differentiation 46 
Materials and methods
Selection criteria of intellectual disability patients for this study and ethical approval
The inclusion criteria for this study were that the affected individuals had a severe undiagnosed developmental or early onset pediatric neurological disorder and that samples were available from both unaffected parents. Written consent was obtained from each patient family using a UK multicenter research ethics approved research protocol (Scottish MREC 05/MRE00/74). 
Sequencing and quality control
Alignment and variant calling
The de-multiplexing was performed using bcl2fastq (2.17.1.14) allowing 1 mismatch when assigning reads to a barcodes. Adapters were trimmed during the demultiplexing process. Raw reads were aligned to the human reference genome (build GRCh38) using the Burrows-Wheeler Aligner (BWA) mem (0.7.13) 47 . The duplicated fragments were marked using samblaster (0.1.22) 48 . The local indel realignment and base quality recalibration was performed using Genome Analysis Toolkit (GATK; 3.4-0-g7e26428) [49] [50] [51] . For each genome SNVs and indels were identified using GATK (3.4-0-g7e26428) HaplotypeCaller 52 creating a gvcf file for each genome. The gvcf files of all the individuals from the same family were merged together and regenotyped using GATK GenotypeGVCFs producing single VCF file per family.
Variant filtering
Variant Quality Score Recalibration pipeline from GATK [49] [50] [51] was used to filter out sequencing and data processing artifacts (potentially false positive SNV calls) from true SNV and indel calls. First step was to create a Gaussian mixture model by looking at the distribution of annotation values of each input variant call set that match with the HapMap 3 sites and Omni 2.5M SNP chip array polymorphic sites, using GATK VariantRecalibrator. Then, VariantRecalibrator applies this adaptive error model to both known and novel variants discovered in the call set of interest to evaluate the probability that each call is real. Next, variants were filtered using GATK ApplyRecalibration such that final variant call set contains all the variants with 0.99 or higher probability to be a true variant call.
De novo mutations (DNM) calling and filtering
The de novo mutations (DNMs) were called using GATK Genotype Refinement workflow. First, genotype posteriors were calculated using sample pedigree information and the allele accounts from 1000 genome sequence data as a prior.
Next, the posterior probabilities were calculated at each variant site for each sample of the trio. Genotypes with genotype quality (GQ) < 20 based on the posteriors are filtered out. All the sites at which both the parents genotype was homozygous reference (0/0) and child's genotype was heterozygous (0/1), with GQs >= 20 for each sample of the trio, were annotated as the high confidence DNMs. Only high confident DNMs that were novel or had minor allele frequency less than 0.01 in 1000 genome were selected for further analysis.
DNM annotations
DNM annotations were performed using Annovar 53 . To access DNM location with respect to genes, refseq, ENSEMBL and USCS annotations were used. To determine allele frequencies, 1000 genome, dbSNP, Exac and GnomAD databases were used. To determine pathogenicity of coding DNMs, annotations were performed with CADD, DANN, EIGAN, FATHMM and GERP++ pathogenicity prediction scores.
In addition, we determined whether any coding DNM has been reported in ClinVar database as a pathogenic mutation.
Structural variant detection and filtering
To detect structural variants (SV), we used four complimentary SV callers: 58 . The MetaSV is the integrative SV caller, which merges SV calls from multiple orthogonal SV callers to detect SV with high accuracy. We selected SVs that were called by at least two independent SV callers out of four.
To detect de-novo SV, we used SV2 59 . SV2 is a machine-learning algorithm for genotyping deletions and duplications from paired-end whole genome sequencing data. In de novo mode SV2 uses trio information to detect de novo SVs at high accuracy.
Fetal brain specific enhancers and other tissue specific enhancers
Roadmap Epigenomic Project 14 chromHMM segmentations across 127 tissues and cell type were used to define brain specific enhancers. All the genic (intronic) and intergenic enhancers ("6_EnhG and 7_Enh) from male (E081) and female fetal brain (E082) samples were extracted. Genome-wide chromHMM chromatin state classification was performed in rolling 200bp windows. All the consecutive 200bp windows assigned as an enhancer in fetal brain were merged to get enhancer boundaries. A score was assigned to each enhancer based on the total number of 200pb windows covered by each enhancer. Next, for each fetal brain enhancer, we counted the number of 200bp segments assigned as an enhancer in the remaining 125 tissues and cell types. This provided enhancer scores across 127 tissues and cell types for all fetal brain enhancers. To identify fetal brain specific enhancers, Z scores were calculated for each fetal brain enhancer using the enhancer scores. Z scores were calculated independently for the male and female fetal brain enhancers.
Independent Z score cutoffs were used for both male and female fetal brain enhancers such that approximately 35% of enhancers were selected. Furthermore, we intersected these enhancers with DNAse-seq data from male and female fetal brain respectively. The fetal brain specific enhancers that overlap with DNAse hypersensitivity sites were selected. Next, the male and female fetal brain specific enhancers were merged together to get final set of 27,420 fetal brain specific enhancers. We used similar approach to identify tissue specific enhancers for selected fetal and adult non-brain tissues.
Human gain enhancers
Human gain enhancers published previously by Reilly et al 15 were downloaded from Gene Expression Omnibus (GEO) using accession number GSE63649.
De novo mutations from healthy individuals
We downloaded de novo mutations identified in healthy individual in genomes of the Netherland (GoNL) study 21 
Fetal brain specific genes
Roadmap Epigenomic Project 14 gene expression (RNA-seq) data from 57 tissues was used to identify fetal brain specific genes. Fetal brain specific genes were identified using only female fetal brain gene expression data, as RNA-seq data was available only for female fetal brain. For each gene, Z scores were calculated using RPKM values across 57 tissues. The genes with Z score greater than two were considered as the brain specific genes.
De novo mutation enrichment analysis
The expected number of de novo mutations (DNMs) in fetal brain specific enhancers and human gain enhancers was estimated using the previously defined framework for de novo mutations 20 . The framework for the null mutation model is based on trinucleotide context where the second base is mutated. Using this framework, the probability of mutation for each enhancer was estimated based on the DNA sequence of the enhancer. Probability of mutation of all the enhancers within the enhancer set (fetal brain specific enhancers and human gain enhancers) was summed to estimate the probability of mutation for the entire enhancer set. The probability of mutation for fetal brain specific enhancers and human gain enhancers was estimated separately. To estimate the expected number of DNMs, the probability of mutation for each enhancer set was multiplied by the cohort size (n=47). To estimate the significance of observed number of DNMs over expected number, Poisson distribution probabilities were invoked using R function ppois.
DNM effect on transcription factor binding
The R bioconductor package motifbreakR 60 was used to estimate the effect of DNM on transcription factor binding. The motifbreakR works with position probability matrices (PPM) for transcription factors (TF). MotifbreakR was run using three different TF databases: viz. homer, encodemotif and hocomoco. To avoid false TF binding site predictions, either with reference allele or with alternate allele, stringent threshold of 0.95 was used for motif prediction. DNMs that show a strong effect on transcription factor binding, as predicted by motifbreakR, were selected for further analysis.
Prediction of target genes of enhancers
Three different methods were used to predict the potential target genes of enhancers.
Chromosome conformation capture (Hi-C) comprehensively detects chromatin interactions in the nucleus; however, it is challenging to identify individual promoterenhancer interactions using Hi-C due to the complexity of the data. In contrast, promoter capture Hi-C (PCHi-C) specifically identifies promoter-enhancer interactions as it uses sequence capture to enrich the interactions involving promoters of annotated genes 43 . The significant interactions between promoters and enhancers identified using PCHi-C in neuronal progenitor cells 22 were used to assign target genes to the DNM containing enhancers. The enhancers were overlapped with the PCHi-C HindIII fragments. If an overlap was found between an enhancer and the PCHi-C HindIII fragment, the significantly interacting regions (PCHi-C HindIII fragments representing promoters of the genes) of the PCHi-C HindIII fragment were extracted to assign genes to the enhancers.
For an enhancer to interact with a promoter, both promoter and enhancer need to be active in specific cells at a specific stage. To identify promoter-enhancer interactions, all the active promoters in fetal brain (as defined by chromHMM segmentation) were extracted. Promoter-enhancer interactions occur within topologically associated domains (TAD), hence, promoters that were located within the same TAD as that of a DNM containing enhancer were used for analysis.
For each enhancer and promoter, H3K27ac counts were extracted from all tissues for which H3K27ac data was available in the Roadmap Epigenomic Project 14 ChIPseq dataset. For fetal brain, H3K27ac ChIP-seq data published by Reilly et al 15 was used because H3K27ac ChIP-seq data was not available in Roadmap Epigenomic Project ChIP-seq dataset for fetal brain. The Spearman rank correlation coefficient (Spearman's rho) was calculated between each enhancer-promoter pair within the TAD using Scipy stats.spearmanr function from Python. The permutation test was performed to identify the significance of the correlation. The counts were randomly shuffled, independently for enhancers and promoters, 1000 times to calculate an adjusted P value. The interactions with an adjusted P value less than 0.01 were considered as a significant interaction between the enhancer and promoter.
Finally, if any enhancer remained unassigned to a gene using these approaches, they were assigned to fetal brain expressed genes within the TAD. A gene with an expression level more than or equal to 1 TPM in the Roadmap Epigenomic Project fetal brain RNA-seq data was considered to be expressed in the fetal brain.
Gene enrichment analysis
To test if enhancer associated genes were enriched for genes previously implicated in neurodevelopmental disorders, three different gene sets were used. 
CRISPR interference lentivirus preparation and transduction
293FT cells were transfected with 3 rd generation system lentiviral plasmids 
Statistical analysis
All luciferase experiments and gene quantification using qPCR were done in biological triplicates. The significance level was calculated using two-tailed t-test.
RNA-seq and data analysis
RNA-seq libraries using RNA extracted from control LUHMES cells, LUHMES cells with CSMD1 enhancer CRISPRi, control differentiated neurons and CRISPRi differentiated neurons were generated in triplicate. RNA-seq libraries were sequenced on one lane of Illumina Hi-seq 4000 with 75bp paired end sequencing.
Sequencing data for RNA-Seq samples are adapter trimmed using Fastp and mapped against a reference transcriptome using splice aware aligner STAR v 2.6.1 61 . We generate raw counts per gene using the FeatureCounts tool (v1.6.3) 62 .
The differential expression analysis was performed using DEseq2 63 . 
